Matthew S. McCammant

Person

Newark, DE, US

People

Patents Grantslast 30 patents

Information Patent Grant
Quinoline compounds as inhibitors of KRAS
- Patent number 11,939,328
- Issue date Mar 26, 2024
- Incyte Corporation
- Qinda Ye
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Tricyclic heterocycles as FGFR inhibitors
- Patent number 11,897,891
- Issue date Feb 13, 2024
- Incyte Corporation
- Matthew S. McCammant
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fused pyrimidine derivatives as A2A/A2B inhibitors
- Patent number 11,873,304
- Issue date Jan 16, 2024
- Incyte Corporation
- Xiaozhao Wang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fused pyrimidine derivatives as A2A / A2B inhibitors
- Patent number 11,168,089
- Issue date Nov 9, 2021
- Incyte Corporation
- Xiaozhao Wang
- C07 - ORGANIC CHEMISTRY

Patents Applicationslast 30 patents

Information Patent Application
QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
- Publication number 20240368152
- Publication date Nov 7, 2024
- INCYTE CORPORATION
- Qinda YE
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS
- Publication number 20240368156
- Publication date Nov 7, 2024
- INCYTE CORPORATION
- Onur ATASOYLU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CYCLIC UREA KRAS INHIBITORS
- Publication number 20240358702
- Publication date Oct 31, 2024
- INCYTE CORPORATION
- Onur ATASOYLU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
- Publication number 20240287086
- Publication date Aug 29, 2024
- INCYTE CORPORATION
- Matthew S. McCammant
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
- Publication number 20230226040
- Publication date Jul 20, 2023
- INCYTE CORPORATION
- Alejandro Amador Arjona
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
- Publication number 20230144051
- Publication date May 11, 2023
- INCYTE CORPORATION
- Qinda YE
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS
- Publication number 20210261555
- Publication date Aug 26, 2021
- INCYTE CORPORATION
- Xiaozhao Wang
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
- Publication number 20210171535
- Publication date Jun 10, 2021
- INCYTE CORPORATION
- Matthew S. McCammant
- C07 - ORGANIC CHEMISTRY
Information Patent Application
IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
- Publication number 20210139485
- Publication date May 13, 2021
- INCYTE CORPORATION
- Xiaozhao Wang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS
- Publication number 20190375752
- Publication date Dec 12, 2019
- INCYTE CORPORATION
- Xiaozhao Wang
- C07 - ORGANIC CHEMISTRY
Information Patent Application
IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
- Publication number 20190292188
- Publication date Sep 26, 2019
- INCYTE CORPORATION
- Xiaozhao Wang
- C07 - ORGANIC CHEMISTRY

Matthew S. McCammant

Person

Patents Grantslast 30 patents

Quinoline compounds as inhibitors of KRAS

Tricyclic heterocycles as FGFR inhibitors

Fused pyrimidine derivatives as A2A/A2B inhibitors

Fused pyrimidine derivatives as A2A / A2B inhibitors

Patents Applicationslast 30 patents

QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS

2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS

CYCLIC UREA KRAS INHIBITORS

TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS

COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR

QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS

FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS

TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS

IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS

FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS

IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS